Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits

Its latest report of clinical data suggests it has a winner on its hands.Every big pharma company relies on a roster of just a few blockbuster drugs -- medicines that reliably bring in more than $1 billion in revenue every year -- to fund its core efforts, and to deliver solid returns to investors. So when a business like Vertex Pharmaceuticals (VRTX -1.02%) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big development.On that not ...